國家衛生研究院 NHRI:Item 3990099045/5205
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 913291      線上人數 : 1169
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/5205


    題名: Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay
    作者: Yang, CC;Hsieh, YC;Lee, SJ;Wu, SH;Liao, CL;Tsao, CH;Chao, YS;Chern, JH;Wu, CP;Yueh, A
    貢獻者: Institute of Biotechnology and Pharmaceutical Research
    摘要: Dengue virus (DENV) causes disease globally with an estimated 25 to 100 million new infections per year. At present, no effective vaccine is available and treatment is supportive. In this study, we identified a potent and selective small-molecule inhibitor, BP2109, of the DENV NS2B/NS3 protease by high-throughput screening assay using recombinant protease complex consisting of central hydrophilic portion of NS2B and N-terminus of protease domain. BP2109 inhibited DENV (serotype 1-4) but not Japanese encephalitis virus (JEV) replication and viral RNA synthesis without detectable cytotoxicity. The compound inhibited recombinant DENV-2 NS2B/NS3 protease with an IC50 value of 15.43 +/- 2.12 muM and reduced the reporter expression of the DENV-2 replicon with an EC50 value of 0.17 +/- 0.01 muM. Sequencing analyses of several individual clones derived from BP2109-resistant DENV-2 RNAs revealed that two amino acid substitutions (R55K and E80K) are found in the region of NS2B, a cofactor of NS2B/NS3 protease complex. The introduction of R55K and E80K double mutations into the dengue NS2B/NS3 protease and a dengue replicon construct conferred 10.3- and 73.8-fold resistance to BP2109, respectively. The E80K mutation was further determined as the key mutation conferring dengue replicon drug resistance (61.3-fold) to BP2109, whereas the R55K mutation alone did not affect drug resistance to BP2109. Both R55K and E80K mutations are located at the central hydrophilic portion of NS2B cofactor where extensive interactions with NS3pro domain exist. Thus, our data provide evidence that BP2109 likely inhibits DENV by a novel mechanism.
    日期: 2011-01
    關聯: Antimicrobial Agents and Chemotherapy. 2011 Jan;55(1):229-238.
    Link to: http://dx.doi.org/10.1128/aac.00855-10
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0066-4804&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000285577400028
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=78650636283
    顯示於類別:[趙宇生(2002-2013)] 期刊論文
    [岳嶽] 期刊論文
    [李秀珠] 期刊論文
    [陳志豪] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB20937790.pdf709KbAdobe PDF1013檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋